Presentation is loading. Please wait.

Presentation is loading. Please wait.

Stephanie J. Lee, Loretta A. Williams 

Published byCordelia Alexander Modified over 5 years ago

Similar presentations

Presentation on theme: "Stephanie J. Lee, Loretta A. Williams "— Presentation transcript:

1 Patient-Reported Outcomes for Acute Graft-versus-Host Disease Prevention and Treatment Trials 
Stephanie J. Lee, Loretta A. Williams  Biology of Blood and Marrow Transplantation  Volume 16, Issue 3, Pages (March 2010) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure 1 Examples of items from the MOS-SF36 (Medical Outcomes Study Short-Form 36), FACT-BMT (Functional Assessment of Cancer Therapy-Bone Marrow Transplant module), and MDASI (M.D. Anderson Symptom Inventory). See text for details. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © Terms and Conditions

Download ppt "Stephanie J. Lee, Loretta A. Williams "

Similar presentations

Utilization and Outcome of Bone Marrow Transplantation in Children with Sickle Cell Disease: A Pediatric Health Information System Database Analysis 

Utilization and Outcome of Bone Marrow Transplantation in Children with Sickle Cell Disease: A Pediatric Health Information System Database Analysis 
Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic.

Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic.
Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease  Shuichiro Takahashi, MD, Daigo Hashimoto,

Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease  Shuichiro Takahashi, MD, Daigo Hashimoto,
Stephanie J. Lee, Loretta A. Williams 

Stephanie J. Lee, Loretta A. Williams 
Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation
Clinical Evaluation of Oral Chronic Graft-Versus-Host Disease

Clinical Evaluation of Oral Chronic Graft-Versus-Host Disease
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 
Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease
Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease  Fevzi F. Yalniz, Mehrdad Hefazi, Kristen.

Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease  Fevzi F. Yalniz, Mehrdad Hefazi, Kristen.
Marlene Z. Cohen, PhD, RN, FAAN, Cathy L. Rozmus, DSN, RN, Tito R

Marlene Z. Cohen, PhD, RN, FAAN, Cathy L. Rozmus, DSN, RN, Tito R
Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,
Acute Graft-Versus-Host Disease in the Setting of T Cell Depletion: Validation of a New Agvhd Risk Score  Hayder Saeed, MD, Stacey Slone, MS, Swati Yalamanchi,

Acute Graft-Versus-Host Disease in the Setting of T Cell Depletion: Validation of a New Agvhd Risk Score  Hayder Saeed, MD, Stacey Slone, MS, Swati Yalamanchi,
Dasatinib as Salvage Therapy for Steroid Refractory and Imatinib Resistant or Intolerant Sclerotic Chronic Graft-versus-Host Disease  Isabel Sánchez-Ortega,

Dasatinib as Salvage Therapy for Steroid Refractory and Imatinib Resistant or Intolerant Sclerotic Chronic Graft-versus-Host Disease  Isabel Sánchez-Ortega,
Implementation of Post-Transplant Assessment Tools for Improved Accuracy of Graft- Versus-Host Disease Reporting  Madhu Ragupathi, Jaskiran Kaur, Luda.

Implementation of Post-Transplant Assessment Tools for Improved Accuracy of Graft- Versus-Host Disease Reporting  Madhu Ragupathi, Jaskiran Kaur, Luda.
Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia  Laura Grein Cavalcanti, Renata L. Fuentes Araújo,

Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia  Laura Grein Cavalcanti, Renata L. Fuentes Araújo,
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease  Paul A. Carpenter, Paul Hoffmeister, Charles.

Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease  Paul A. Carpenter, Paul Hoffmeister, Charles.
A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 

Similar presentations

Ads by Google